RU2009103638A - Трансмукозальное введение 2,3-диметокси-5-метил-6-(10-гидроксидецил)-1,4-бензохинона - Google Patents
Трансмукозальное введение 2,3-диметокси-5-метил-6-(10-гидроксидецил)-1,4-бензохинона Download PDFInfo
- Publication number
- RU2009103638A RU2009103638A RU2009103638/15A RU2009103638A RU2009103638A RU 2009103638 A RU2009103638 A RU 2009103638A RU 2009103638/15 A RU2009103638/15 A RU 2009103638/15A RU 2009103638 A RU2009103638 A RU 2009103638A RU 2009103638 A RU2009103638 A RU 2009103638A
- Authority
- RU
- Russia
- Prior art keywords
- use according
- treatment
- idebenone
- administered
- mucous membrane
- Prior art date
Links
- -1 10-HYDROXYDECYL Chemical class 0.000 title 1
- 239000003814 drug Substances 0.000 claims abstract 12
- JGPMMRGNQUBGND-UHFFFAOYSA-N idebenone Chemical compound COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O JGPMMRGNQUBGND-UHFFFAOYSA-N 0.000 claims abstract 6
- 229960004135 idebenone Drugs 0.000 claims abstract 6
- 210000004400 mucous membrane Anatomy 0.000 claims abstract 6
- 201000002169 Mitochondrial myopathy Diseases 0.000 claims abstract 4
- 201000006938 muscular dystrophy Diseases 0.000 claims abstract 4
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract 2
- 208000014644 Brain disease Diseases 0.000 claims abstract 2
- 206010062346 Congenital neuropathy Diseases 0.000 claims abstract 2
- 208000032274 Encephalopathy Diseases 0.000 claims abstract 2
- 208000024412 Friedreich ataxia Diseases 0.000 claims abstract 2
- 208000009564 MELAS Syndrome Diseases 0.000 claims abstract 2
- 208000012902 Nervous system disease Diseases 0.000 claims abstract 2
- 208000025966 Neurological disease Diseases 0.000 claims abstract 2
- 208000018737 Parkinson disease Diseases 0.000 claims abstract 2
- 239000000443 aerosol Substances 0.000 claims abstract 2
- 229940112822 chewing gum Drugs 0.000 claims abstract 2
- 235000015218 chewing gum Nutrition 0.000 claims abstract 2
- 210000001072 colon Anatomy 0.000 claims abstract 2
- 229940079593 drug Drugs 0.000 claims abstract 2
- 208000023692 inborn mitochondrial myopathy Diseases 0.000 claims abstract 2
- 208000006443 lactic acidosis Diseases 0.000 claims abstract 2
- 238000004519 manufacturing process Methods 0.000 claims abstract 2
- 208000012268 mitochondrial disease Diseases 0.000 claims abstract 2
- 230000002438 mitochondrial effect Effects 0.000 claims abstract 2
- 230000000926 neurological effect Effects 0.000 claims abstract 2
- 208000018360 neuromuscular disease Diseases 0.000 claims abstract 2
- 210000001328 optic nerve Anatomy 0.000 claims abstract 2
- 239000000829 suppository Substances 0.000 claims abstract 2
- 229940124597 therapeutic agent Drugs 0.000 claims abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Toxicology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
1. Применение идебенона для получения медикамента для трансмукозального введения. ! 2. Применение по п.1 для получения медикамента для лечения митохондриальных, неврологических и нервномышечных заболеваний. ! 3. Применение по п.2 для лечения атаксии Фридрейха, врожденной нейропатии зрительного нерва Лебера, митохондриальной миопатии, энцефалопатии, лактоацидоза с инсультоподобными эпизодами (синдрома MELAS) и митохондриальных миопатий. ! 4. Применение по п.2 для лечения миодистрофии Дюшенна и миодистрофии Беккера. ! 5. Применение по п.2 для лечения болезни Альцгеймера или болезни Паркинсона. ! 6. Применение по любому из пп.1-5, отличающееся тем, что идебенон вводят в дозировке от 0,01 до 60 мг/кг/ день. ! 7. Применение по любому из пп.1-5, отличающееся тем, что идебенон вводят в дозировке от 0,01 до 20 мг/кг/ день. ! 8. Применение по любому из пп.1-5, отличающееся тем, что медикамент имеет форму суппозитория, капель, жевательной резинки, быстрорастворимой таблетки или аэрозоля. ! 9. Применение по любому из пп.1-5, отличающееся тем, что медикамент вводят через слизистую оболочку носа, слизистую оболочку рта или слизистую оболочку толстой кишки. ! 10. Применение по любому из пп.1-5, отличающееся тем, что медикамент содержит второй терапевтический агент.
Claims (10)
1. Применение идебенона для получения медикамента для трансмукозального введения.
2. Применение по п.1 для получения медикамента для лечения митохондриальных, неврологических и нервномышечных заболеваний.
3. Применение по п.2 для лечения атаксии Фридрейха, врожденной нейропатии зрительного нерва Лебера, митохондриальной миопатии, энцефалопатии, лактоацидоза с инсультоподобными эпизодами (синдрома MELAS) и митохондриальных миопатий.
4. Применение по п.2 для лечения миодистрофии Дюшенна и миодистрофии Беккера.
5. Применение по п.2 для лечения болезни Альцгеймера или болезни Паркинсона.
6. Применение по любому из пп.1-5, отличающееся тем, что идебенон вводят в дозировке от 0,01 до 60 мг/кг/ день.
7. Применение по любому из пп.1-5, отличающееся тем, что идебенон вводят в дозировке от 0,01 до 20 мг/кг/ день.
8. Применение по любому из пп.1-5, отличающееся тем, что медикамент имеет форму суппозитория, капель, жевательной резинки, быстрорастворимой таблетки или аэрозоля.
9. Применение по любому из пп.1-5, отличающееся тем, что медикамент вводят через слизистую оболочку носа, слизистую оболочку рта или слизистую оболочку толстой кишки.
10. Применение по любому из пп.1-5, отличающееся тем, что медикамент содержит второй терапевтический агент.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83749606P | 2006-08-14 | 2006-08-14 | |
| EP06016935A EP1891946A1 (en) | 2006-08-14 | 2006-08-14 | Transmucosal administration of 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone |
| EP06016935.6 | 2006-08-14 | ||
| US60/837496 | 2006-08-14 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2009103638A true RU2009103638A (ru) | 2010-09-27 |
| RU2429830C2 RU2429830C2 (ru) | 2011-09-27 |
Family
ID=37564291
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2009103638/15A RU2429830C2 (ru) | 2006-08-14 | 2007-08-03 | Трансмукозальное введение 2,3-диметокси-5-метил-6-(10-гидроксидецил)-1,4-бензохинона |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20090208425A1 (ru) |
| EP (2) | EP1891946A1 (ru) |
| JP (2) | JP5665167B2 (ru) |
| CN (1) | CN101541317B (ru) |
| AU (1) | AU2007286491B2 (ru) |
| BR (1) | BRPI0715901A2 (ru) |
| CA (1) | CA2660577C (ru) |
| CY (1) | CY1117860T1 (ru) |
| ES (1) | ES2574087T3 (ru) |
| HU (1) | HUE029241T2 (ru) |
| IL (1) | IL196745A (ru) |
| MX (1) | MX2009001674A (ru) |
| NZ (1) | NZ574422A (ru) |
| PL (1) | PL2051706T3 (ru) |
| PT (1) | PT2051706T (ru) |
| RU (1) | RU2429830C2 (ru) |
| SI (1) | SI2051706T1 (ru) |
| WO (1) | WO2008019769A1 (ru) |
| ZA (1) | ZA200900902B (ru) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2108366B1 (en) | 2008-04-09 | 2011-10-19 | Santhera Pharmaceuticals (Schweiz) AG | Idebenone for the treatment of respiratory illness in muscular dystrophy |
| EP2246048A1 (en) | 2009-04-30 | 2010-11-03 | Santhera Pharmaceuticals (Schweiz) AG | Quinone derivative 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone for the treatment of primary progressive multiple sclerosis |
| SI2605769T1 (sl) | 2010-08-16 | 2016-10-28 | Santhera Pharmaceuticals (Schweiz) Ag | Derivati benzokinona za zdravljenje mitohondrijskih očesnih bolezni |
| CN102091038B (zh) * | 2011-01-20 | 2012-07-25 | 天津大学 | 艾地苯醌纳米脂质载体透皮吸收制剂及制备方法 |
| US10806703B2 (en) * | 2012-01-20 | 2020-10-20 | Lts Lohmann Therapie-System Ag | Transmucosal administration system for a pharmaceutical drug |
| EP2620141A1 (en) | 2012-01-25 | 2013-07-31 | Santhera Pharmaceuticals (Schweiz) AG | Thin film drug delivery system for the transmucosal administration of a 1,4-benzoquinone derivative |
| US9750705B2 (en) | 2012-08-31 | 2017-09-05 | The Regents Of The University Of California | Agents useful for treating obesity, diabetes and related disorders |
| US20150150790A1 (en) * | 2013-12-04 | 2015-06-04 | Jao Hung Biotechnology Co., Ltd. | Transdermal enhancer |
| DE102017104277A1 (de) | 2017-03-01 | 2018-09-06 | Lts Lohmann Therapie-Systeme Ag | Transmukosales Verabreichungssystem für Idebenon |
| US20230127518A1 (en) | 2020-03-19 | 2023-04-27 | Bemido Sa | Idebenone for the treatment of acute respiratory distress syndrome (ards) in patients diagnosed with a coronavirus infection |
| WO2022258629A1 (en) | 2021-06-07 | 2022-12-15 | Katholieke Universiteit Leuven | Idebenone in the treatment of drug resistant epilepsy |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2503571B2 (ja) * | 1988-02-26 | 1996-06-05 | 武田薬品工業株式会社 | 脳循環代謝改善剤 |
| JPH07103018B2 (ja) * | 1988-09-16 | 1995-11-08 | 武田薬品工業株式会社 | 精神分裂病治療剤 |
| DE69331839T2 (de) * | 1992-01-29 | 2002-12-12 | Takeda Chemical Industries Ltd | Schnellösliche Tablette und ihre Herstellung |
| EP0915696B1 (en) * | 1996-07-11 | 2002-05-29 | Takeda Chemical Industries, Ltd. | ANTI-beta-AMYLOID PROTEIN-INDUCED CYTOTOXICITY COMPOSITION |
| JPH11116470A (ja) * | 1997-08-12 | 1999-04-27 | Takeda Chem Ind Ltd | イデベノン含有経皮投与製剤 |
| NZ504108A (en) * | 1997-09-26 | 2002-06-28 | Noven Pharma | Bioadhesive compositions comprising a polyvinylpyrrolidone polymer and methods for topical administration of active agents |
| CA2272971C (en) * | 1998-10-29 | 2008-01-15 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Quinone derivatives for treating or preventing diseases associated with iron overload |
| SE9803760D0 (sv) * | 1998-11-04 | 1998-11-04 | Jan Hedner | Sätt att behandla och diagnostisera syndromet restless legs och motsvarande medel |
| DE60044134D1 (de) * | 1999-08-26 | 2010-05-20 | Takeda Pharmaceutical | Nasenschleimhaut haftende matrix |
| JP2003026567A (ja) * | 2001-05-10 | 2003-01-29 | Kanegafuchi Chem Ind Co Ltd | 補酵素ｑを有効成分とする粘膜投与用組成物 |
| ATE328283T1 (de) * | 2002-07-01 | 2006-06-15 | Santhera Pharmaceuticals Ch | Screeningverfahren und verbindungen zur behandlung von friedreich ataxia |
| US20040067986A1 (en) * | 2002-10-04 | 2004-04-08 | Nathan Sassover | Neuro-degenerative inhibitor, neuro-endocrine modulator, and neuro-cerebral metabolism enhancer |
| EP1618881A1 (en) * | 2004-07-20 | 2006-01-25 | Santhera Pharmaceuticals (Schweiz) GmbH | Use of non-glucocorticoid steroids for the treatment of muscular dystrophy |
| CN1838969A (zh) * | 2004-10-07 | 2006-09-27 | 三仪股份有限公司 | 经皮和经粘膜制剂 |
| CA2602290C (en) * | 2005-03-21 | 2012-01-17 | Santhera Pharmaceuticals (Schweiz) Ag | Quinone derivative 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1 ,4- benzoquinone for the treatment of muscular dystrophies |
-
2006
- 2006-08-14 EP EP06016935A patent/EP1891946A1/en not_active Withdrawn
-
2007
- 2007-08-03 ES ES07801511.2T patent/ES2574087T3/es active Active
- 2007-08-03 AU AU2007286491A patent/AU2007286491B2/en not_active Ceased
- 2007-08-03 BR BRPI0715901-3A patent/BRPI0715901A2/pt not_active Application Discontinuation
- 2007-08-03 RU RU2009103638/15A patent/RU2429830C2/ru active
- 2007-08-03 JP JP2009524098A patent/JP5665167B2/ja active Active
- 2007-08-03 WO PCT/EP2007/006895 patent/WO2008019769A1/en active Application Filing
- 2007-08-03 MX MX2009001674A patent/MX2009001674A/es active IP Right Grant
- 2007-08-03 HU HUE07801511A patent/HUE029241T2/en unknown
- 2007-08-03 NZ NZ574422A patent/NZ574422A/en not_active IP Right Cessation
- 2007-08-03 CA CA2660577A patent/CA2660577C/en active Active
- 2007-08-03 SI SI200731778A patent/SI2051706T1/sl unknown
- 2007-08-03 CN CN200780030147.3A patent/CN101541317B/zh active Active
- 2007-08-03 PT PT78015112T patent/PT2051706T/pt unknown
- 2007-08-03 PL PL07801511.2T patent/PL2051706T3/pl unknown
- 2007-08-03 US US12/375,586 patent/US20090208425A1/en not_active Abandoned
- 2007-08-03 EP EP07801511.2A patent/EP2051706B1/en active Active
-
2009
- 2009-01-27 IL IL196745A patent/IL196745A/en active IP Right Grant
- 2009-02-06 ZA ZA200900902A patent/ZA200900902B/xx unknown
-
2013
- 2013-01-11 JP JP2013003311A patent/JP5907901B2/ja not_active Expired - Fee Related
-
2016
- 2016-07-27 CY CY20161100744T patent/CY1117860T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL196745A0 (en) | 2009-11-18 |
| EP2051706A1 (en) | 2009-04-29 |
| JP2013100319A (ja) | 2013-05-23 |
| US20090208425A1 (en) | 2009-08-20 |
| WO2008019769A1 (en) | 2008-02-21 |
| EP2051706B1 (en) | 2016-05-11 |
| CN101541317B (zh) | 2015-04-15 |
| NZ574422A (en) | 2011-04-29 |
| AU2007286491B2 (en) | 2010-06-24 |
| BRPI0715901A2 (pt) | 2013-08-06 |
| JP2010500384A (ja) | 2010-01-07 |
| HUE029241T2 (en) | 2017-02-28 |
| RU2429830C2 (ru) | 2011-09-27 |
| JP5665167B2 (ja) | 2015-02-04 |
| MX2009001674A (es) | 2009-02-25 |
| IL196745A (en) | 2016-10-31 |
| EP1891946A1 (en) | 2008-02-27 |
| CA2660577C (en) | 2012-05-01 |
| PT2051706T (pt) | 2016-07-18 |
| CN101541317A (zh) | 2009-09-23 |
| CY1117860T1 (el) | 2017-05-17 |
| ZA200900902B (en) | 2010-07-28 |
| SI2051706T1 (sl) | 2016-06-30 |
| ES2574087T3 (es) | 2016-06-14 |
| AU2007286491A1 (en) | 2008-02-21 |
| CA2660577A1 (en) | 2008-02-21 |
| PL2051706T3 (pl) | 2016-11-30 |
| JP5907901B2 (ja) | 2016-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2009103638A (ru) | Трансмукозальное введение 2,3-диметокси-5-метил-6-(10-гидроксидецил)-1,4-бензохинона | |
| Gomathi et al. | Drug studies on Rett syndrome: from bench to bedside | |
| NZ605887A (en) | Pharmaceutical dosage form comprising 6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4’,9’-dihydro-3’h-spiro[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine for the treatment of neuropathic pain | |
| ES2916649T1 (es) | Composiciones y usos para el tratamiento de la esclerosis múltiple | |
| HUP0204023A2 (hu) | Pirrolidinacetamidszármazék alkalmazása önmagában vagy kombinációban központi idegrendszeri zavarok kezelésére és ezeket tartalmazó gyógyszerkészítmények | |
| RU2008119454A (ru) | Лекарственное средство для защиты моторного нейрона у пациентов с боковым амиотрофическим склерозом | |
| ES2742373T3 (es) | Una composición de combinación | |
| MXPA05012810A (es) | Formas de dosis oral de memantina. | |
| JP2016521755A5 (ru) | ||
| NZ613291A (en) | Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof | |
| AR045289A1 (es) | Forma de dosificacion oral de liberacion controlada que comprende 4-(2-di-n-propilaminoetil) - 2(3h)-indolona (ropi-nirol) y uso de dicha forma de dosificacion para la elaboracion de un medicamento | |
| RU2009123536A (ru) | Стабильные парентеральные составы, включающие ингибиторы pcb на основе бензодиазепина | |
| ES2643167T3 (es) | Procedimiento de producción y uso de un copolímero de carboximetilcelulosa sódica y gosipol | |
| RU2011111792A (ru) | Применение парацетамола и ибупрофена в лечении | |
| ES2313880T3 (es) | Procedimiento para el tratamiento de la icontinencia. | |
| RU2012108144A (ru) | Противораковая терапия, направленная против раковых стволовых клеток и форм рака, устойчивых к лечению лекарственными препаратами | |
| CA2612179A1 (en) | A pharmaceutical composition comprising loratadine and its use to treat patients with upper respiratory mucosal congestion | |
| CN1853619B (zh) | 阿戈美拉汀在获得用于治疗双相性精神障碍的药物中的用途 | |
| TNSN06072A1 (en) | Use of oxcarbazepine for the treatment of diabetic neuropathic pain and the improvement of sleep | |
| JPWO2019073408A5 (ru) | ||
| TW448044B (en) | Pharmaceutical composition of selegiline for the treatment of epileptic disorders | |
| MXPA01010340A (es) | Osanetant en el tratamiento de transtornos del humor. | |
| Soman et al. | Adverse effects of drugs on salivary glands | |
| ES2782898T3 (es) | Métodos de administración de compuestos agonistas de la trombopoyetina | |
| HRP20220905T1 (hr) | Novi centralno aktivni agonist ghrelina i njegove medicinske uporabe |